Flerie advances TOL2 into pivotal myasthenia gravis clinical trials

Flerie has reached a key stage in the development of TOL2, a drug aimed at treating myasthenia gravis. The company has completed the integration of Toleranzia AB, shifting its flagship project into a critical phase of clinical testing.

Shareholders recently approved a bonus share issue, with allocations set for May 18, 2026. Meanwhile, the firm has chosen to reinvest profits rather than pay dividends for the past fiscal year. Flerie has fully absorbed Toleranzia AB's operations, transferring its business to Bonsai Biotherapeutics AB, a Flerie subsidiary. This move consolidates the development of TOL2, a drug candidate designed to address the autoimmune disease myasthenia gravis.

The treatment is now in Phase I/IIa clinical trials, which focus on safety, tolerability, and early signs of effectiveness. Testing is underway across several core European markets, including Germany, though the exact number of trial centres remains unspecified.

To support TOL2's progress, Flerie has decided against dividend payments for the last financial year. Instead, funds will be redirected into product development. The company's annual general meeting in March 2026 also approved a bonus share issue, with May 18, 2026, set as the record date for allocations. TOL2's ongoing trials mark a significant step in Flerie's pipeline, with analysts noting its potential to change myasthenia gravis treatment. The company's financial decisions, including the bonus share issue and dividend reinvestment, reflect a focus on advancing the drug's development. Shareholders will receive bonus shares by the May 2026 deadline.